Language:

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Cell, 2021-10, Vol.184 (21), p.5432-5447.e16 [Peer Reviewed Journal]

2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021 Elsevier Inc. 2021 Elsevier Inc. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2021.09.015 ;PMID: 34619077

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Author: Walls, Alexandra C. ; Miranda, Marcos C. ; Schäfer, Alexandra ; Pham, Minh N. ; Greaney, Allison ; Arunachalam, Prabhu S. ; Navarro, Mary-Jane ; Tortorici, M. Alejandra ; Rogers, Kenneth ; O’Connor, Megan A. ; Shirreff, Lisa ; Ferrell, Douglas E. ; Bowen, John ; Brunette, Natalie ; Kepl, Elizabeth ; Zepeda, Samantha K. ; Starr, Tyler ; Hsieh, Ching-Lin ; Fiala, Brooke ; Wrenn, Samuel ; Pettie, Deleah ; Sydeman, Claire ; Sprouse, Kaitlin R. ; Johnson, Max ; Blackstone, Alyssa ; Ravichandran, Rashmi ; Ogohara, Cassandra ; Carter, Lauren ; Tilles, Sasha W. ; Rappuoli, Rino ; Leist, Sarah R. ; Martinez, David R. ; Clark, Matthew ; Tisch, Roland ; O’Hagan, Derek T. ; Van Der Most, Robbert ; Van Voorhis, Wesley C. ; Corti, Davide ; McLellan, Jason S. ; Kleanthous, Harry ; Sheahan, Timothy P. ; Smith, Kelly D. ; Fuller, Deborah H. ; Villinger, Francois ; Bloom, Jesse ; Pulendran, Bali ; Baric, Ralph S. ; King, Neil P. ; Veesler, David
Subjects: COVID-19 ; mosaic nanoparticle ; receptor-binding domain ; sarbecovirus ; SARS-CoV-2 ; self-assembling nanoparticle ; spike glycoprotein ; vaccine design
Is Part Of: Cell, 2021-10, Vol.184 (21), p.5432-5447.e16
Description: Understanding vaccine-elicited protection against SARS-CoV-2 variants and other sarbecoviruses is key for guiding public health policies. We show that a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle (RBD-NP) vaccine protects mice from SARS-CoV-2 challenge after a single immunization, indicating a potential dose-sparing strategy. We benchmarked serum neutralizing activity elicited by RBD-NPs in non-human primates against a lead prefusion-stabilized SARS-CoV-2 spike (HexaPro) using a panel of circulating mutants. Polyclonal antibodies elicited by both vaccines are similarly resilient to many RBD residue substitutions tested, although mutations at and surrounding position 484 have negative consequences for neutralization. Mosaic and cocktail nanoparticle immunogens displaying multiple sarbecovirus RBDs elicit broad neutralizing activity in mice and protect mice against SARS-CoV challenge even in the absence of SARS-CoV RBD in the vaccine. This study provides proof of principle that multivalent sarbecovirus RBD-NPs induce heterotypic protection and motivates advancing such broadly protective sarbecovirus vaccines to the clinic. [Display omitted] •RBD-NP enables dose-sparing and protects mice after only one dose•RBD-NP elicits diverse polyclonal antibody responses in non-human primates•RBD-NP and HexaPro confer similar resilience to antigenic drift•Mosaic and cocktail RBD-NPs protect against heterotypic SARS-CoV challenge A clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle (RBD-NP) vaccine is protective in mice after a single immunization and elicits strong antibody responses across circulating mutants and some sarbecoviruses. Multivalent sarbecovirus RBD-NP vaccines elicit heterotypic protection against sarbecoviruses.
Publisher: United States: Elsevier Inc
Language: English
Identifier: ISSN: 0092-8674
EISSN: 1097-4172
DOI: 10.1016/j.cell.2021.09.015
PMID: 34619077
Source: Cell Press Free Archives

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021 Elsevier Inc. 2021 Elsevier Inc. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2021.09.015 ;PMID: 34619077

Searching Remote Databases, Please Wait